DPP4 and COVID-19: Noteworthy here is the higher percentage of patients with cardiac conditions, or cardiac conditions and diabetes, using anti-hyperglycemics, especially DPP4 inhibitors, and to a lower degree SGLT2 inhibitors in the non-severe COVID-19 cohort.